What we do Patel Chem Specialities Limited manufactures specialty cellulose-based chemicals used as excipients in pharmaceuticals, food, and cosmetics industries, crucial for product formulation. |
Founded in 2,008 |
Market share A recognized manufacturer with US-FDA approved Vatva plant, serving domestic and export markets with growing market presence. |
Problem solved Provides essential excipients that improve drug formulation, food texture, and cosmetic product stability, addressing quality and performance needs. |
Top clients or who we serve Pharmaceutical companies, food and beverage manufacturers, cosmetic producers; primarily B2B clients domestically and internationally. |
Key management - |
Our journey and innovations Founded in 2008, converted to public limited in 2024, launched IPO in 2025, and gained US-FDA approval for Vatva unit in 2025. |
Where we operate Operations in India with manufacturing in Vatva and Talod; exports contribute around 18% of revenue. |
Top products or what we offer Key products include Sodium Monochloro Acetate, Sodium Starch Glycolate, Croscarmellose Sodium, Carboxymethyl Cellulose variants, and Microcrystalline Cellulose. |
Top brands - |
Raw materials needed Cellulose derivatives and chemical intermediates such as Sodium Monochloro Acetate. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is largely recurring, based on continuous supply contracts in pharmaceutical and food sectors. |
Our industry position Growing specialty chemical firm with US-FDA approval, steadily increasing revenue and profit margins. |
Financial highlights FY2024 revenue approx. Rs 105 crore with net profit of Rs 10.57 crore, showing strong growth from previous years. |
Geographical revenue split Domestic sales constitute about 83%, exports about 17% of total revenue as of FY2025. |
Order book - |
Whats driving growth Rising demand for pharmaceutical excipients, new US-FDA approval facilitating exports, and increasing industrial applications. |
Our future plans Focus on expanding production capabilities, enhancing export markets, and innovation in specialty chemical products. |
Our green promise - |
Our people and values - |
Key challenges ahead Global economic uncertainties, raw material price volatility, and regulatory compliance risks. |
Interesting facts Vatva unit is US-FDA approved enhancing global market credibility; IPO raised Rs 58.8 crore in 2025. |
Risks and strategy Risks include competition and regulation; strategy includes compliance adherence and diversification of product applications. |
